Induction of Experimental Atherosclerosis
General Considerations
Experimental atherosclerosis was first successfully induced in rabbits by Saltykow (1908) and Ignatowski (1909). During the following years, various scientists found that dietary cholesterol was the responsible stimulus for development of atherosclerosis . Other species are also susceptible to diet-induced atherosclerosis (Reviews by Kritchevsky 1964; Hadjiinky et al. 1991). Mouse models of atherosclerosis were reviewed by Reardon and Getz (2001) and by Daugherty (2002). Tailleux et al. (2003) underlined the importance of nuclear receptors, e. g., peroxisome proliferators‐activated receptors (PPARs), liver X receptors (LXR) (Joseph and Totonoz 2003; Terasaka et al. 2003) and retinoid receptors (RXR) (Staels 2001; Li et al. 2005), which are implicated in lipid metabolism and inflammation.
References and Further Reading
Daugherty A (2002) Mouse models of atherosclerosis. Am J Med Sci 323:3–10
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References and Further Reading
Abe I, Prestwich GD (1998) Development of new cholesterol‐lowering drugs. Drug Dev Today 3:389–390
Abe I, Zheng YF, Prestwich GD (1998a) Mechanism based inhibitors and other active-site targeted inhibitors of oxidosqualene cyclase and squalene cyclase. J Enzyme Inhib 13:385–398
Abe I, Zheng YF, Prestwich GD (1998b) Photoaffinity labeling of oxidosqualene cyclase and squalene cyclase by a benzophenone‐containing inhibitor. Biochemistry 37:5779–5784
Abletshauser C, Klüßendorf D, Schmidt A, Winkler K, März W, Buddecke E, Malmstan M, Siegel G (2002) Biosensing of arteriosclerotic nanoplaque formation and interaction with an HMG CoA reductase inhibitor. Acta Physiol Scand 176:131–145
Ahn YS, Smith D, Osada J, Li Z, Schaefer EJ, Ordovas M (1994) Dietary fat saturation affects apolipoprotein gene expression and high density lipoprotein size distribution in golden Syrian hamsters. J Nutr 124:2147–2155
Åkerlund JE, Björkhem I (1990) Studies on the regulation of cholesterol 7α-hydroxylase and HMG-CoA reductase in rat liver: effects of lymphatic drainage and ligation of the lymph duct. J Lipid Res 31:2159–2166
Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusi U, Rudling M, Angelin B, Björkhem I, Pettersson S, Gustavsson JA (2001) Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J Clin Invest 107:565–573
Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20:470–475
Amano Y, Nishimoto T, Tozawa R, Ishikawa E, Imura Y, Sugiyama Y (2003) Lipid-lowering effects of TAK-475, a squalene synthase inhibitor: animal models of familial hypercholesterolemia. Eur J Pharmacol 466:155–161
Amin D, Cornell SA, Gustafson DK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Biphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657–1663
Amin D, Gustafson SK, Weinacht JM, Cornell SA, Neuenschwander K, Kosmider B, Scotese AC, Regan JR, Perrone MH (1993) RG 12561 (Dalvastatin): A novel synthetic inhibitor of HMG-CoA reductase and cholesterol‐lowering agent. Pharmacology 46:13–22
Amin D, Rutledge RZ, Needle SN, Galczenski HF, Neuenschwander K, Scotese AC, Maguire MP, Bush RC, Hele DJ, Bilder GE, Perrone MH (1997) RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol‐lowering agent: comparison with inhibitors of HMG-CoA reductase. J Pharmacol Exp Ther 281:746–752
Amin D, Rutledge RZ, Needle SN, Hele DJ, Neuenschwander K, Bush RC, Bilder GE, Perrone MH (1996) RPR 101821, a new potent cholesterol‐lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase. Naunyn‐Schmiedebergs Arch Pharmacol 353:233–240
Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA (2001) Mevastin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32:980–986
Aoki T, Yoshinaka Y, Yamazaki H, Suzuki H, Tamaki T, Sato F, Kitahara M, Saito Y (2002) Triglyceride‐lowering effect of pivastatin in a rat model of postprandial lipemia. Eur J Pharmacol 444:107–113
Arimura N, Horiba T, Imagawa M, Shimizu M, Sato R (2004) The peroxisome proliferator‐activated receptor γ regulates expression of the perilipin gene in adipocytes. J Biol Chem 279:10070–10076
Asakawa T, Matsushita S (1980) Coloring conditions of thiobarbituric acid test for detecting lipid hydroperoxides. Lipids 15:137–140
Assmann G, Shriewer H, Schmitz G, Hägele EO (1983) Quantification of high-density‐lipoprotein cholesterol by precipitation with phosphotungstic acid/MgCl2. Clin Chem 29:2026–2030
Ast M, Frishman WH (1990) Bile acid sequestrants. J Clin Pharmacol 30:99–106
Avigan J, Bhathena SJ, Schreiner ME (1975) Control of sterol synthesis and of hydroxymethylglutaryl CoA reductase in skin fibroblasts grown from patients with homozygous type II hyperlipoproteinemia. J Lipid Res 16:151–154
Bae S-H, Lee JN, Fitzky BU, Seong J, Paik Y-K (1999) Cholesterol biosynthesis from lanosterol. Molecular cloning, tissue distribution, expression, chromosomal location and regulation of rat 7-dehydrocholesterol reductase, a Smith-Lemli-Opitz syndrome‐related protein. J Biol Chem 274:14624–14631
Baetta R, Camera M, Comparato C, Altana C, Ezekowitz MD, Tremoli E (2002) Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 22:692–698
Baker FC, Schooley DA (1979) Analysis and purification of acyl coenzyme A thioesters by reversed-phase ion-pair liquid chromatography. Anal Biochem 94:417–424
Balasubramaniam S, Simons LA, Chang S, Roach PD, Nestel PJ (1990) On the mechanism by which an ACAT inhibitor (CL 277,082) influences plasma lipoproteins in the rat. Atherosclerosis 82:1–5
Barish GD, Evans RM (2004) PPARs and LXRs: atherosclerosis goes nuclear. Trends Endocrinol Metab 15:158–165
Barnhart RL, Busch SJ, Jackson RL (1989) Concentration‐dependent antioxidant activity of probucol in low density lipoproteins in vitro: probucol degradation precedes lipoprotein oxidation. J Lipid Res 30:1703–1710
Baxter A, Fitzgerald BJ, Hutson JL, McCarthy AD, Motteram JM, Ross BC, Sapra M, Snowden MA, Watson NS, Williams RJ, Wright C (1992) Squalestatin 1, a potent inhibitor of squalene synthase, which lowers cholesterol in vivo. J Biol Chem 267:11705–11708
Beck G, Kesseler K, Baader E, Bartmann W, Bergmann A, Granzer E, Jendralla H, von Kerekjarto B, Krause R, Paulus E, Schubert W, Wess G (1990) Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine‐substituted 3,5-dihydroxy-6-heptenoic (heptanoic) acids. J Med Chem 33:52–60
Becker RHA, Wiemer G, Linz W (1991) Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 18 (Suppl 2):S110–S115
Beere PA, Glagov S, Zarins ChK (1992) Experimental atherosclerosis at the carotid bifurcation of the cynomolgus monkey. Arterioscl Thrombos 12:1245–1253
Beitz J, Mest HJ (1991) A new derivative of tradipil (AR 12456) as a potentially new antiatherosclerotic drug. Cardiovasc Drug Rev 9:385–397
Bell FP, Gammil RB, John LCS (1992) U-73482: A novel ACAT inhibitor that elevates HDL‐cholesterol, lowers plasma triglyceride and facilitates hepatic cholesterol mobilization in the rat. Atherosclerosis 92:115–122
Berkenboom G, Unger P, Fontaine J (1989) Atherosclerosis and responses of human isolated coronary arteries to endothelium‐dependent and -independent vasodilators. J Cardiovasc Pharmacol 14, Suppl 11:S35–S39
Bernheim F, Bernheim MLC, Wilbur KM (1948) The reaction between thiobarbituric acid and the oxidation products of certain lipids. J Biol Chem 174:257–264
Bernini F, Corsini A, Fumagalli R, Paoletti R (1994) Pharmacology of lipoprotein receptors. J Lipid Mediat Cell Signal 9:9–17
Berthou L, Duverger N, Emmanuel F, Langouët S, Auwerx J, Guillouzo A, Fruchart JC, Rubin E, Denèfle P, Staels B, Branellec D (1996) Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97:2408–2416
Bilheimer DW, Watanabe Y, Kita T (1982) Impaired receptor‐mediated catabolism of low density lipoprotein in the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci USA 79:3305–3309
Biller SA, Forster C, Gordon EM, Harrity T, Rich LC, Marretta J, Ciosek CP (1991a) Isoprenyl phosphinylformates: new inhibitors of squalene synthetase. J Med Chem 34:1912–1914
Biller SA, Sofia MJ, DeLange B, Forster C, Gordon EM, Harrity T, Rich LC, Ciosek CP (1991b) The first potent inhibitor of squalene synthase: a profound contribution of an ether oxygen to inhibitor‐enzyme interaction. J Am Chem Soc 113:8522–8524
Björkhem I, Andersson U, Sudjama‐Sugiaman E, Eggertsen G, Hylemon Ph (1993) Studies on the link between HMG-CoA reductase and cholesterol 7α-hydroxylase in lymph-fistula rats: evidence for both transcriptional and post‐transcriptional mechanisms for down‐regulation of the two enzymes by bile acids. J Lipid Res 34:1497–1503
Blaton V, Peeters H (1976) The nonhuman primates as models for studying atherosclerosis: Studies on the chimpanzee, the baboon and the rhesus macacus. In: Day CE (ed) Atherosclerosis Drug Discovery, Plenum Press, New York and London, pp 33–64
Bocan TMA, Ferguson E, McNally W, Uhlendorf PD, Mueller SB, Dehart P, Sliskovic DR, Roth BD, Krause BR, Newton RS (1992) Hepatic and non hepatic sterol synthesis and tissue distribution of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim Biophys Acta 1123:133–144
Bocan TMA, Mazur MJ, Mueller SB, Brown EQ, Sliskovic DR, O'Brien PM, Creswell MW, Lee H, Uhlendorf PD, Roth BD, Newton RS (1994) Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 111:127–142
Bocan TMA, Mueller SB, Uhlendorf PD, Newton RS, Krause BR (1991) Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. Arterioscler Thrombosis 11:1830–1843
Bocan TMA, Muellers BAK, Uhlendorf PD, Quenby-Brown E, Mazur MJ, Black AE (1993) Inhibition of acyl-CoA:cholesterol O-acyl transferase reduces the cholesterol enrichment of atherosclerotic lesions in the Yucatan micropig. Atherosclerosis 99:175–186
Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA (1998) A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in the aortic lesions of LDL receptor‐deficient mice. J Clin Invest 101:353–345
Booth RGF, Martin JF, Honey AC, Hassall DG, Beesley JE, Moncada S (1989) Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis 76:257–268
Bossaller C, Habib GB, Yamamoto H, Williams C, Wells S, Henry PD (1987) Impaired muscarinic endothelium‐dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 79:170–174
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248
Braughler JM, Pregenzer JF, Chase RL, Duncan LA, Jacobsen EJ, McCall JM (1987) Novel 21-amino steroids as potent inhibitors of iron‐dependent lipid peroxidation. J Biol Chem 262:10438–10440
Bravo E, Cantafora A, Calcobrini A, Ortu G (1994) Why prefer the golden Syrian hamster (Mesocricetus auratus) to the Wistar rats in experimental studies on plasma lipoprotein metabolism. Comp Biochim Physiol Vol. 107B: pp 347–355
Bretherton KN, Day AJ, Skinner SL (1977) Hypertension-accelerated atherogenesis in cholesterol-fed rabbits. Atherosclerosis 27:79–87
Brown MS, Goldstein JL, Dietschy JM (1979) Active and inactive forms of 3-hydroxyx-3-methylglutaryl coenzyme A reductase in the liver of the rat. J Biol Chem 254:5144–5149
Bruckdorfer KR (1990) Free radicals, lipid peroxidation and atherosclerosis. Curr Opin Lipidol 1:529–535
Brun RP, Tontonoz P, Forman B, Ellis R, Chen J, Evans RM, Spiegelman BM (1996) Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev 15:974–984
Bursill CA, Channon KM, Greaves DC (2004) The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics. Curr Opin Lipidol 15:145–149
Caldwell CT, Suydam DE (1959) Quantitative study of estrogen‐induced atherosclerosis in cockerels. Proc Soc Exp Biol Med 101:299–302
Cardin AD, Holdsworth G, Jackson RL (1984) Isolation and characterization of plasma lipoproteins and apolipoproteins. In: Schwartz A (ed) Methods in Pharmacology, Vol 5. Plenum Press, New York and London, pp 141–166
Carew TE, Schwenke DC, Steinberg D (1987) Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 84:7725–7729
Carlson LA, Rössner S (1972) A methodological study of an intravenous fat tolerance test with Intralipid emulsion. Scand J Clin Lab Invest 29:271–280
Cattel L, Ceruti M, Balliano G, Viola F, Grosa G, Schuber F (1989) Drug design based on biosynthetic studies: synthesis, biological activity, and kinetics of new inhibitors of 2,3-oxidosqualene cyclase and squalene epoxidase. Steroids 53:363–391
Cayen MN, Dvornik D (1979) Effect of diosgenin on lipid metabolism in rats. J Lipid Res 20:162–174
Chan C, Andreotti D, Cox B, Dymock BW, Hutson JL, Keeling SE, McCarthy AD, Procopiou PA, Ross BC, Sareen M, Scicinski JJ, Sharatt PJ, Snowden MA, Watson MS (1996) The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors. J Med Chem 39:207–215
Chang CCY, Huh HY, Cadigan KM, Chang TY (1993) Molecular cloning and functional expression of human acyl-coenzyme A:cholesterol acyltransferase cDNA in mutant Chinese hamster ovary cells. J Biol Chem 268:20747–20755
Chapman KP, Stafford WW, Day CE (1976) Produced by selective breeding of Japanese quail animal model for experimental atherosclerosis. In: Day CE (ed) Atherosclerosis Drug Discovery, Plenum Press, New York and London, pp 347–356
Chawla A, Boisvert WA, Lee CH, Laffitte BH, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss KL, Evans RM, Tontonoz P (2001) A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161–171
Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, Liao D, Han J, Kang H, Evans RM (2003) PPARδ is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100:1268–1273
Chen HW, Kandutsch AA (1976) Effects of cholesterol derivatives on sterol biosynthesis. In: Day CE (ed) Atherosclerosis Drug Discovery. Plenum Press, New York and London, pp 405–417
Chen Z, Ishibashi S, Perrey S, Osuga JI, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N (2001) Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice. Pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21:372–377
Chiang JY, Stroup D (1994) Identification and characterization of a putative bile-acid‐responsive element in the cholesterol 7α-hydroxylase gene promoter. J Biol Chem 269:17502–17507
Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, Staels B (2000) CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator‐activated receptors. Circulation 101:2411–2417
Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B (1998) Activation of proliferator‐activated receptors alpha and gamma induces apoptosis of human monocyte‐derived macrophages. J Biol Chem 273:255573–25580
Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Pineda Torra I, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B (2001) PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53–38
Chugh A, Ray A, Gupta JB (2003) Squalene epoxidase as hypocholesterolemic drug revisited. Prog Lipid Res 42:37–50
Ciosek CP Jr, Magnin DR, Harrity DW, Logan JV, Dickson JK Jr, Gordon EM, Hamilton KA, Jolibois KG, Kunselman LK, Lawrence RM (1993) Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem 268:24832–24837
Clader JW (2004) The discovery of ezetimibe: a view from outside the receptor. J Med Chem 47:1–9
Clark SB, Tercyak AM (1984) Reduced cholesterol transmucosal transport in rats with inhibited mucosal acyl CoA:cholesterol acyltransferase and normal pancreatic function. J Lipid Res 25:148–159
Clarkson TB, Lofland HB (1961) Therapeutic studies on spontaneous arteriosclerosis in pigeons. In: Garattini S, Paoletti R (eds) Drugs affecting lipid metabolism. Elsevier Publ Comp., Amsterdam, pp 314–317
Clinkenbeard KD, Sugiyama T, Reed WD, Lane MD (1975) Cytoplasmatic 3-hydroxy-3-methylglutaryl coenzyme A synthase from liver. Purification, properties, and role in cholesterol synthesis. J Biol Chem 250:3124–3135
Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE (2001) Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor deficient mice. Atheroscler Thromb Vasc Biol 21:365–371
Corti R, Osende JI, Fallon JT, Fuster V, Mizsei G, Jneid H, Wright SD, Chaplin WF, Badimon JJ (2004) The selective peroxisomal proliferator‐activated receptor-gamma agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis. In vivo study by high‐resolution magnetic resonance imaging. J Am Coll Cardiol 43:464–473
Cosgrove PG, Gaynor BJ, Harwood HJ (1992) Quantitation of hepatic low density lipoprotein receptor levels in the hamster. FASEB J 4:A533
Cosgrove PG, Gaynor BJ, Harwood HJ Jr (1992) Quantitation of hepatic LDL receptor levels in the hamster. FASEB J 4:A533
Costet P, Luo Y, Wang N, Tall AR (2000) Sterol dependent activation of the ABC1 promotor by the liver Xrecptor/retinoid X receptor. J Biol Chem 36:28240–28245
Crook D, Weisgraber KH, Rall SC Jr, Mahley RW (1990) Isolation and characterization of several plasma apolipoproteins of common marmoset monkey. Arteriosclerosis 10:625–632
Curtius HCh, Bürgi W (1966) Gaschromatographische Bestimmung des Serumcholesterins. Z klin Chem klin Biochem 4:38–42
D'Costa MA, Smigura FC, Kulhay K, Angel A (1977) Effects of clofibrate on lipid synthesis, storage, and plasma intralipid clearance. J Lab Clin Med 90:823–836
Daugherty A (2002) Mouse models of atherosclerosis. Am J Med Sci 323:3–10
Davies MG, Klyachkin ML, Kim JH, Hagen PO (1993) Endothelin and vein bypass grafts in experimental atherosclerosis. J Cardiovasc Pharmacol 22, Suppl 8:S348–S351
Day CE (1990) Comparison of hypocholesterolemic activities of the bile acid sequestrants cholestyramine and cholestipol hydrochloride in cholesterol fed sea quail. Artery 17:281–288
Day CE, Phillips WA, Schurr PE (1979) Animal models for an integrated approach to the pharmacologic control of atherosclerosis. Artery 5:90–109
Day CE, Stafford WW (1975) New animal model for atherosclerosis research. In: Kritchevsky D, Paoletti R, Holmes WL (eds) Lipids, Lipoproteins, and Drugs. Plenum Press, New York, pp 339–347
Day CE, Stafford WW, Schurr PE (1977) Utility of a selected line (SEA) of the Japanese quail (Coturnix coturnix japonica) for the discovery of new anti‐atherosclerosis drugs. Anim Sci 27:817–821
DeBlasi A, O'Reilly K, Motulsky HY (1989) Calculation receptor number from binding experiments using same compound as radioligand and competitor. Trends Pharmacol Sci 10:227–229
DeCampli WM, Kosek JC, Mitchell RS, Handen CE, Miller DC (1988) Effects of aspirin, dipyridamole, and cod liver oil on accelerated myointimal proliferation in canine veno-arterial allografts. Ann Surg 208:746–754
Delerive P, Furman C, Teissier E, Fruchart JC, Duriez P, Staels B (2000) Oxidized phospholipids activate PPARα in a phospholipase A2‐dependent manner. FEBS Lett 471:34–38
Delsing DJ, Jukema JW, van de Wiel MA, Emeis JJ, van der Laarse A, Havekes LM, Princen HM (2003) Differential effects of amlodipin and atorvastin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol 42:63–70
Desvergne B, Wahli W (1999) Peroxisome proliferator‐activated receptors: nuclear control of metabolism. Endocrinol Rev 20:649–688
Dietschy JM, Spady DK (1984) Measurement of rates of cholesterol synthesis using tritiated water. J Lipid Res 25:1469–1476
Dole VP, Meinertz H (1960) Microdetermination of long-chain fatty acids in plasma and tissues. J Biol Chem 235:2595–2599
Dollis D, Schuber F (1994) Effects of a 2,3-oxidosqualene‐lanosterol cyclase inhibitor 2,3:22,23-dioxidosqualene and 24,25-epoxycholesterol on the regulation of cholesterol biosynthesis in human hepatoma cell line HepG2. Biochem Pharmacol 48:49–57
Dresel HA, Deigner HP, Frübis J, Strein K, Schettler G (1990) LDL‐metabolism of the arterial wall – new implications for atherogenesis. Z Kardiol 79: Suppl. 3:9–16
Dressel U, Allen TL, Pippal JP, Rohde PR, Lau P, Muscat GEO (2003) The peroxisome proliferator‐activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17:2477–2493
Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fiévet C, Wright SD, Staels B (2002) Reduction of atherosclerosis by the peroxisome proliferators‐activated receptor α agonist fenofibrate in mice. J Biol Chem 277:48051–48057
Dufresne C, Jones ETT, Omstead MN, Bergstrom JD, Wilsin KE (1996) Novel zaragozic acids from Leptodontidium elatius. J Nat Prod 59:52–54
Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8:422–430
Eggen DA, Bhattacharyya AK, Strong JP, Newman III WP, Guzman MA, Restrepo C (1991) Use of serum lipid and apolipoprotein concentrations to predict extent of diet-induced atherosclerotic lesions in aortas and coronary arteries and to demonstrate regression of lesions in individual Rhesus monkeys. Arterioscl Thrombos 11:467–475
Eggstein M, Kreutz FH (1966a) Eine neue Bestimmung der Neutralfette im Blutserum und Gewebe. I. Mitteilung. Prinzip, Durchführung und Besprechung der Methode. Klin Wschr 44:262–267
Eggstein M, Kreutz FH (1966b) Eine neue Bestimmung der Neutralfette im Blutserum und Gewebe. II. Mitteilung. Zuverlässigkeit der Methode, andere Neutralfettbestimmungen, Normalwerte für Triglyceride und Gycerin im menschlichen Blut. Klin Wschr 44:267–273
Einarsson K, Benthin L, Ewerth S, Hellers G, Stwåhlberg D, Angelin B (1989) Studies on acyl-CoA:cholesterol acyltransferase activity in human liver microsomes. J Lipid Res 30:739–746
Eisele B, Budzinski R, Müller P, Maier R, Mark M (1997) Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res 38:564–575
Esterbauer H, Rotheneder M, Striegl G, Waeg G, Ashy A, Sattler W, Jürgens G (1989) Vitamin E and other lipophilic anti-oxidants protect LDL against oxidation. Fat Sci Technol 91:316–324
Etgen GJ, Mantio N (2003) PPAR ligands for metabolic disorders. Curr Top Med Chem 3:1649–1661
Farhy RD, Ho KL, Carretero OA, Scicli AG (1992) Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 182:283–288
Fears R, Brown R, Ferres H, Grenier F, Tyrell AWR (1990) Effects of novel bile salts on cholesterol metabolism in rats and guinea-pigs. Biochem Pharmacol 40:2029–2037
Fernandez ML (2001) Guinea pigs as model for cholesterol and lipoprotein metabolism. J Nutr 131:10–20
Ferré P (2004) The biology of peroxisome proliferator‐activated receptors. Relationship with lipid metabolism and insulin sensitivity. Diabetes 53 [Suppl 1]:S43–S50
Field FJ, Albright E, Mathur S (1991) Inhibition of acylcoenzyme A:cholesterol acyltransferase by PD 128042: effect on cholesterol metabolism and secretion in CaCo-2 cells. Lipids 26:1–8
Field FJ, Salome RG (1982) Effect of dietary fat saturation, cholesterol and cholestyramine on acyl CoA:cholesterol acyltransferase activity in rabbit intestinal microsomes. Biochim Biophys Acta 712:557–570
Fillios LC, Andrus StB, Mann GV, Stare FJ (1956) Experimental production of gross atherosclerosis in the rat. J Exper Med 104:539–552
Finta KM, Fischer MJ, Lee L, Gordon D, Pitt B, Webb RC (1993) Ramipril prevents impaired endothelium‐dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis 100:149–156
Fleckenstein-Grün, Frey M, Thimm F, Fleckenstein A (1992) Protective effects of various calcium antagonists against experimental arteriosclerosis. J Human Hypertens 6, Suppl 1:S13–S18
Flint OP, Masters BA, Gregg RE, Durham SK (1997) Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 145:91–98
Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509
Forman BM, Chen J, Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator‐activated receptors. Proc Natl Acad Sci USA 94:4312–4317
Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann D, Noonan DJ, Burke LT, McMorris T, Lamph WW, Evans RM, Weinberger C (1995b) Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:687–693
Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman PM, Evans RM (1995) 15-Deoxy-δ 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803–812
Francis GA, Annicotte JS, Auwerx J (2003) PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 3:186–191
Francis GA, Knopp RH, Oram JF (1995) Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-1 in Tangier disease. J Clin Invest 96:78–87
Frantz ID, Hinkelman BT (1955) Acceleration of hepatic cholesterol synthesis by Triton WR-1339. J Exp Med 101:225–232
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin Chem 18:499–502
Fronek K (1990) Calcium antagonists and experimental atherosclerosis. Cardiovasc Drug Rev 8:229–237
Fu T, Kashireddy P, Borensztajn J (2003) The peroxisome-proliferator‐activated receptor α agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem J 373:941–947
Fukushima H, Aono S, Nakamura Y, Endo M, Imai T (1969) The effect of N-(α-methylbenzyl)linoleamide on cholesterol metabolism in rats. J Atheroscler Res 10:403–414
Fukushima H, Nakatani H (1969) Cholesterol‐lowering effects of DL-N-(α-methylbenzyl)-linoleamide and its optically active isomers in cholesterol-fed animals. J Atheroscler Res 9:65–71
Gallagher PJ, Nanjee MN, Richards T, Roche WR, Miller NE (1988) Biochemical and pathological features of a modified strain of Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 71:173–183
Gallo LL, Wadsworth JA, Vahouny GV (1987) Normal cholesterol absorption in rats deficient in intestinal acyl co-enzyme A:cholesterol acyltransferase activity. J Lipid Res 28:381–387
Garattini S, Paoletti P, Paoletti R (1958) The effect of diphenylethylacetic acid on cholesterol and fatty acid biosynthesis. Arch Int Pharmacodyn 117:114–122
Garattini S, Paoletti R, Bizzi L, Grossi E, Vertua R (1961) A comparative evaluation of hypocholesteremizing drugs on several tests. In: Garattini S, Paoletti R (eds) Drugs affecting lipid metabolism. Elsevier Publ Comp., Amsterdam, pp 144–157
Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML (2003) Liver peroxisome proliferator‐activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278:34268–34276
Gebhardt R (1993) Multiple inhibitory effects of garlic extracts on cholesterol biosynthesis in hepatocytes. Lipids 28:613–619
Gerst N, Schuber F, Viola F, Cattel L (1986) Inhibition of cholesterol biosynthesis in 3T3 fibroblasts by 2-aza-2,3-dihydrosqualene, a rationally designed 2,3-oxidosqualene cyclase inhibitor. Biochem Pharmacol 35:4243–4250
Getz GS (1990) The involvement of lipoproteins in atherogenesis: evolving concepts. In: Lee KT, Onodera K, Tanaka K (eds) Atherosclerosis II: Recent Progress in Atherosclerosis Research. Ann NY Acad Sci 598:17–28
Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP (1993) Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors. A double-blind, placebo‐controlled study. J Clin Pharmacol 33:226–229
Gillies PJ, Robinson CS, Rathgeb KA (1990) Regulation of ACAT activity by a cholesterol substrate pool during the progression and regression phases of atherosclerosis: implications for drug discovery. Atherosclerosis 83:177–185
Goetze S, Xi XP, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, Law RE (1999) PPAR gamma ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovasc Pharmacol 33:798–806
Goldstein JL, Basu SK, Brown MS (1983) Receptor mediated endocytosis of LDL in cultured cells. Meth Enzymol 98:241–260
Goldstein JL, Brown MS (1990) Regulation of mevalonate pathway. Nature 343:425–430
Gotoda T, Yamada N, Kawamura M, Kozaki K, Mori N, Ishibashi S, Shimano H, Takaku F, Yazaki Y, Furuichi Y, Murase T (1991) Heterogeneous mutations in the human lipoprotein lipase gene in patients with familial lipoprotein lipase deficiency. J Clin Invest 88:1856–1864
Gotteland JP, Loubat C, Planty B, Junquero D, Delhon A, Halazy S (1998) Sulfonamide derivatives of benzylamine block cholesterol biosynthesis in HepG-2 cells: a new type of squalene epoxidase inhibitors. Bioorg Med Chem Lett 8:1337–1342
Gotto AM (1990) Pravastatin: A hydrophilic inhibitor of cholesterol synthesis. J Drug Dev 3:155–161
Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, Grenade LL, Gurwitz JH, Chan KA, Goodman MJ, Platt R (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. J Am Med Assoc 2992:2585–2590
Grayson NA, Westkaemper RB (1988) Stable analogs of acyl adenylates. Inhibition of acetyl- and acyl-CoA synthetase by adenosine 5′-alkylphosphates. Life Sci 43:437–444
Greenspan MD, Yudkovitz JB, Chen JS, Hanf DP, Chang MN, Chiang PYC, Chabala JC, Alberts AW (1989) The inhibition of cytoplasmatic acetoacetyl-CoA thiolase by a triyne carbonate (L-660,631). Biochem Biophys Res Commun 163:548–553
Greenspan MD, Yudkowitz JB, Lo CYL, Chen JS, Alberts AW, Hunt VM, Chang MN, Yang SS, Thompson KL, Chiang YCP, Chabala JC, Monaghan RL, Schwartz RL (1987) Inhibition of hydroxymethylglutaryl‐coenzyme A synthase by L-659,699. Proc Natl Acad Sci USA 84:7488–7492
Grieveson LA, Ono T, Sakakibara J, Derrick JP, Dickinson JM, McMahon A, Higson SPJ (1997) A simplified squalene epoxidase assay based on an HPCL separation and time‐dependent UV/visible determination of squalene. Anal Biochem 252:19–23
Groot PH, van Vlijmen BJ, Benson GM, Hofker MH, Schiffelers R, Vidgeon-Hart M, Haveskes LM (1996) Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol 16:926–933
Groves PH, Levis MJ, Cheadle HA, Penny WJ (1993) SIN-1 reduces platelet adhesion and thrombus formation in a porcine model of balloon angioplasty. Circulation 87:590–597
Ha Y-C, Barter PJ (1982) Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species. Comp Biochem Physiol Vol 71B:265–269
Ha Y-C, Barter PJ (1986) Effects of sucrose feeding and injection of lipid transfer protein on rat plasma lipoproteins. Comp Biochem Physiol B 83:463–466
Ha YC, Barter PJ (1985) Rapid separation of plasma lipoproteins by gel permeation chromatography on agarose gel Superose 6B. J Chromatogr 341:154–159
Hadjiinky P, Bourdillon MC, Grosgogeat Y (1991) Modèles expérimentaux d'athérosclérose. Apports, limites et perspectives. Arch Mal Ceut Vaiss 84:1593–1603
Harada K, Shimano H, Ishibashi S, Yamada N (1996) Transgenic mouse and gene therapy. Diabetes 45 (Suppl 3): S129–S132
Harnett KM, Walsh CT, Zhang L (1989) Effects of Bay o 2752, a hypocholesterolemic agent, on intestinal taurocholate absorption and cholesterol esterification. J Pharm Exp Ther 251:502–509
Harris GH, Dufresne C, Joshua H, Koch LA, Zink DL, Salmon PM, Goklen KE, Kurtz MM, Rew DJ, Bergstrom JD, Wilson KE (1995) Isolation, structure determination and squalene synthase activity of L-731,120 and L-731,128, alkyl citrate analogs of zaragozic acids A and B. Bioorg Med Chem Lett 5:2403–2408
Harris M, Davis W, Brown WV (2003) Ezetimibe. Drugs Today (Barc) 39:229–247
Harris NV, Smith C, Ashton MJ, Bridge AW, Bush RC, Coffee ECJ, Dron DI, Harper MF, Lythgoe DJ, Newton CG, Riddell D (1992) Acyl-CoA:cholesterol O-acyl transferase (ACAT) inhibitors. 1. 2-(Alkylthio)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT. J Med Chem 35:4384–4392
Harwood HJ, Chandler CE, Pellarin LD, Bangerter FW, Wilkins RW, Long CA, Cosgrove PG, Malinow MR, Marzetta CA, Pettini JK, Savoy YE, Mayne JT (1993) Pharmacologic consequences of cholesterol absorption inhibition: alteration in cholesterol metabolism and reduction in plasma cholesterol concentration induced by the synthetic saponin β-tigogenin cellobioside (CP-88818; tiqueside). J Lipid Res 34:377–395
Harwood HJ, Schneider M, Stacpoole PW (1984) Measurement of human leukocyte microsomal HMG-CoA reductase activity. J Lipid Res 25:967–978
Hasty AH, Shimano H, Osuga J, Namatama I, Takahashi A, Yahagi N, Perrey S, Iizuka Y, Tamura Y, Amemiya-Kudo M, Yoshikawa T, Okazaki H, Harada K, Matsuzaka T, Sone H, Gotoda T, Nagai R, Ishibashi S, Yamda N (2001) Severe hypercholesterolemia, hypertriglyceridemia and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J Biol Chem 276:37402–37408
Hatch FT, Lees RS (1968) Practical methods for plasma lipoprotein analysis. In: Paoletti R, Kritchevsky D (eds) Advances in Lipid Research, Vol 6, pp 1–68, Academic Press, New York
Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345–1353
Heffron F, Middleton B, White DA (1990) Inhibition of acyl coenzyme A:cholesterol acyl transferase by trimethylcyclohexanylmandelate (Cyclandelate). Biochem Pharmacol 39:575–580
Heider JG, Pickens CE, Kelly LA (1983) Role of acyl CoA:cholesterol acyltransferase in cholesterol absorption and its inhibition by 57–118 in the rabbit. J Lipid Res 24:1127–1134
Helgerud P, Saarem K, Norum KR (1981) Acyl-CoA:cholesterol acyltransferase in human small intestine: its activity and some properties of the enzymic reaction. J Lipid Res 22:271–277
Heller RA, Gould RG (1973) Solubilization and partial purification of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. Biochem Biophys Res Commun 50:859–865
Henry PD, Bentley KI (1981) Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest 68:1366–1369
Herling AW, Burger HJ, Schubert G, Hemmerle H, Schäfer HL, Kramer W (1999) Alteration of carbohydrate and lipid intermediary metabolism during inhibition of glucose-6-phosphatase in rats. Eur J Pharmacol 386:75–82
Hidaka Y, Hotta H, Nagata Y, Iwasawa Y, Horie M, Kamei T (1991) Effect of a novel squalene epoxidase inhibitor, NB-598, on the regulation of cholesterol metabolism in HEP G2 cells. J Biol Chem 266:13171–13177
Hidaka Y, Sato T, Kamei T (1990) Regulation of squalene epoxidase in HepG2 cells. J Lipid Res 31:2087–2094
Hiyoshi H, Yanagimachi M, Ito M, Ohtsuka I, Yoshida I, Saeki T, Tanaka H (2000) Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. J Lipid Res 41:1136–1144
Hiyoshi H, Yanagimachi M, Ito M, Yasuda N, Okada T, Ikuda H, Shinmyo D, Tanaka K, Kuruso Y, Yoshida I, Saeki T, Tanaka H (2003) Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in hepatocytes. J Lipid Res 44:128–135
Hodgekinson CP, Ye S (2003) Microarray analysis of peroxisome proliferator‐activated receptor γ-induced changes in gene expression in macrophages. Biochem Biophys Res Commun 308:505–510
Hoerer S, Schmid A, Keckel A, Budzinski RM, Nar H (2003) Crystal structure of the human liver X receptor βligand binding domain in complex with a synthetic agonist. J Mol Biol 344:853–861
Hollander W, Prusty S, Nagraj S, Kirkpatrick B, Paddock J, Colombo M (1978) Comparative effects of cetaben (PHB) and dichlormethylene diphosphonate (Cl2MDP) on the development of atherosclerosis in the cynomolgus monkey. Atherosclerosis 31:307–325
Holmes WL (1964) Drugs affecting lipid synthesis. In: Paoletti R (ed) Lipid Pharmacology. Academic Press, New York, London, chapter 3, pp 131–184
Holub WR, Galli FA (1972) Automated direct method for measurement of serum cholesterol, with use of primary standards and a stable reagent. Clin Chem 18:239–243
Horie M, Sawasaki Y, Fukuzumi H, Watanabe K, Iuzuka Y, Tsuchiya Y, Kamei T (1991) Hypolipidemic effects of NB-598 in dogs. Atherosclerosis 88:183–192
Horie M, Tsuchiya Y, Hayashi M, Iida Y, Iwasawa Y, Nagata Y, Sawasaki Y, Fukuzumi H, Kitani K, Kamei T (1990) NB-598: a potent competitive inhibitor of squalene epoxidase. J Biol Chem 265:18075–18078
Howard AN (1976) The baboon in atherosclerosis research: Comyparison with other species and use in testing drugs affecting lipid metabolism. In: Day CE (ed) Atherosclerosis Drug Discovery, Plenum Press, New York and London, pp 77–87
Hsu MH, Palmer CN, Griffin KJ, Johnson EF (1995) A single amino acid change in the mouse peroxisome proliferator‐activated receptor alpha alters transcriptional responses to peroxisome proliferators. Mol Pharmacol 48:559–567
Huettinger M, Herrmann M, Goldenberg H, Granzer E, Leineweber M (1993) Hypolipidemic activity of HOE-402 is mediated by stimulation of the LDL receptor pathway. Atheroscl Thromb 13:1005–1012
Huettinger M, Schneider WJ, Ho YK, Goldstein JL, Brown M (1984) Use of monoclonal anti-receptor antibodies to probe the expression of the low density lipoprotein receptor in tissues of normal and Watanabe heritable hyperlipidemic rabbits. J Clin Invest 74:1017–1026
Huff MW, Telford DE, Edwards JY, Burnett JR, Barrett HP, Rapp SR, Napawan N, Keller BT (2002) Inhibition of the apical sodium‐dependent bile acid transporter reduced LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB. Arterioscler Thromb Vasc Biol 22:1884–1891
Hussain MM, Fatma S, Pan X, Iqbal J (2005) Intestinal lipoprotein assembly. Curr Opin Lipidol 16:281–285
Hussain MM, Strickland DK, Bakillah A (1999) The mammalian low-density lipoprotein receptor family. Annu Rev Nutr 19:141–172
Hylemon PB, Stude EJ, Pandak WM, Heuman DM, Vlahcevic ZR, Chinag JYL (1989) Simultaneous measurement of cholesterol 7α-hydroxylase activity by reverse-phase high‐performance liquid chromatography using both endogenous cholesterol and exogenous [4-14C]cholesterol as substrate. Anal Biochem 182:212–216
Ignatowski A (1909) Über die Wirkung des tierischen Eiweißes auf die Aorta und die parenchymatösen Organe der Kaninchen. Virchow's Arch Pathol Anat Physiol 198:248–270
Ikeda Y, Young LH, Lefer AM (2003) Rosuvastin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 41:649–656
Illingworth DR (1987) Lipid-lowering drugs. An overview of indications and optimum therapeutic use. Drugs 33:259–279
Ingebritson GS, Gibson MD (1981) Assay of enzymes that modulate S-3-hydroxy-3-methylglutaryl coenzyme A reductase by reversible phosphorylation. Meth Enzymol 71:486
Inoue Y, Goto H, Horinuki R, Kimura Y, Toda T (1990) Experimental atherosclerosis in the rat carotid artery induced by balloon de‐endothelialization and hyperlipemia. A histological and biochemical study. J Jpn Atheroscler Soc 18:1147–1154
Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK (1994) Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor‐negative mice. J Clin Invest 93:1885–1893
Ishihara T, Kakuta H, Moritani H, Ugawa T, Sakamoto S, Tsukamoto S, Yanagishawa I (2003) Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors. Bioorg Med Chem 11:2403–2414
Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makashima M, Shimomura I (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenetic factor, by nuclear receptors. Diabetes 52:1655–1663
Jackson CL, Bush RC, Bowyer DE (1988) Inhibitory effects of calcium antagonists on balloon catheter‐induced arterial smooth muscle cell proliferation and lesion size. Atherosclerosis 69:115–122
Jacobsson L (1987) Influence of clofibrate on the plasma lipoprotein pattern and on lipid content and protein and collagen synthesis in atherosclerotic coronary arteries and abdominal aorta from hypercholesterolemic mini-pigs. Atherosclerosis 63:173–180
Jacobsson L, Lundholm L (1982) Experimental atherosclerosis in hypercholesterolemic mini-pigs. Atherosclerosis 45:129–148
Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, Mangelsdorf DJ (1999) Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ. Proc Natl Acad Sci USA 96:266–271
Jayakody L, Kappagoda T, Senaratne MPJ, Thomson ABR (1988) Impairment of endothelium‐dependent relaxation: an early marker for atherosclerosis in the rabbit. Br J Pharmacol 94:335–346
Jaye M (2003) LXR agonists for the treatment of atherosclerosis. Curr Opin Invest Drugs 4:1053–1058
Jendralla H, Baader E, Bartmann W, Beck G, Bergmann A, Granzer E, v. Kerekjarto B, Kesseler K, Krause R, Schubert W, Wess G (1990) Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic(-heptanoic) acids. J Med Chem 33:61–70
Johns W, Bates T (1969) Quantification of the binding tendencies of cholestyramine I: Effect of structure and added electrolytes on the binding of unconjugated and conjugated bile salt anions. J Pharmacol Sci 58:179–183
Johnston TP, Nguyen LB, Chu WA, Shefer S (2001) Potency of selected statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Int J Pharm 229:75–86
Jones SP, Gibson MF, Rimmer DM, Gibson TM, Sharp BR, Lefer DJ (2002) Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40:1172–1178
Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GH, Tran J, Tippin TK, Wang X, Lusis AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P (2002) Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 99:7604–7609
Joseph SB, Totonoz P (2003) LXRs: new therapeutic targets in atherosclerosis? Curr Opin Pharmacol 3:192–197
Jungnickel PW, Cantral KA, Maloley PA (1992) Pravastin: A new drug for the treatment of hypercholesterinemia. Clin Pharm 11:677–689
Junker LH, Story JA (1985) An improved assay for cholesterol 7α-hydroxylase activity using phospholipid liposome‐solubilized substrate. Lipids 20:712–718
Jürgens G (1989) Modified serum lipoproteins and atherosclerosis. Ann Rep Med Chem 25:169–176
Kano H, Hayashi T, Sumi D, Esaki T, Asai Y, Thakur NK, Jayachandran M, Iguchi A (1999) A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up‐regulation of endothelial NO synthase mRNA. Biochem Biophys Res Commun 259:414–419
Kasim SE, Elovson J, Khilnani S, Almario RU, Jen KLC (1993) The effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat. Atherosclerosis 104:147–152
Kawata M, Lee KT, Makiat T (1990) Detection of regenerating cells in the aorta after ballooning by immunocytochemical demonstration of the thymidine analogue 5-bromo-2′-deoxyuridine (BrUdR). In: Lee KT, Onodera K, Tanaka K (eds) Atherosclerosis II: Recent Progress in Atherosclerosis Research. Ann NY Acad Sci 598:514–516
Keller AJ, Correll JW, Ladd AT (1951) Sustained hyperlipemia induced in rabbits by means of intravenous injected surface‐active agents. J Exp Med 93:373–384
Keller G, Kennedy M, Papyannopoulou T, Wiles MV (1993) Hematopoietic commitment during embryonic stem cell differentiation in culture. Mol Cell Biol 13:473–486
Kelm M, Dahmann R, Wink D, Feelisch M (1997) The nitric oxide/superoxide assay. J Biol Chem 272:9922–9932
Kersten S (2002) Peroxisome proliferator activated receptors and obesity. Eur J Pharmacol 440:223–234
Kersten S, Desvergne B, Wahli W (2000) Roles of PPARs in health and disease. Nature 405:421–424
Keul J, Linnet N, Eschenbruch E (1968) The photometric autotitration of free fatty acids. Z Klin Chem Klin Biochem 6:394–398
Kihara K, Toda H, Mori M, Hashimoto M, Mizogami S (1988) The bile acid binding and hypocholesterolemic activity of anion-exchange resins bearing the imidazolium salt group. Eur J Med Chem 23:411–415
Kita T (1991) Oxidized lipoproteins and probucol. Curr Opin Lipidol 2:35–38
Kita T, Brown MS, Bilheimer DW, Goldstein JL (1982) Delayed clearance of very low density and intermediate density lipoproteins with enhanced conversion to low density lipoprotein in WHHL rabbits. Proc Natl Acad Sci USA 79:5693–5697
Kita T, Brown MS, Watanabe Y, Goldstein JL (1981) Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia. Proc Natl Acad Sci USA 78:2268–2272
Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai Ch (1987) Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84:5928–5931
Kita T, Yokode M, Ishii K, Arai H, Nagano Y (1990) The role of atherogenic low density lipoproteins (LDL) in the pathogenesis of atherosclerosis. In: Lee KT, Onodera K, Tanaka K (eds) Atherosclerosis II: Recent Progress in Atherosclerosis Research. Ann NY Acad Sci 598:188–193
Kjeldsen K, Stender S (1989) Calcium antagonists and experimental atherosclerosis. Proc Soc Exp Biol Med 190:219–228
Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM (1994) Differential expression and activation of a family of murine peroxisome receptor‐activated receptors. Proc Natl Acad Sci USA 91:7355–7359
Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM (1992) Convergence of 9-cis retinoic acid and peroxisome signalling pathways through heterodimer formation of their receptors. Nature 358:771–774
Klotz U (2003) Pharmacological comparison of the statins. Arzn Forsch/Drug Res 53:605–611
Knorr AM, Kazda S (1990) Influence of nifedipine on experimental arteriosclerosis. Cardiovasc Drugs Ther 4:1027–1032
Koga S, Horwitz DL, Scanu AM (1969) Isolation and properties of lipoproteins from normal rat serum. J Lipid Res 10:577–588
Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M (1990) Tissue‐selective inhibition of cholesterol synthesis in vivo by pravastin sodium, a 3-hydroxy-3-methylglutaryl‐coenzym A reductase inhibitor. Biochim Biophys Acta 1045:115–120
Kota BP, Huang THW, Roufogalis BD (2005) An overwiew on biological mechanisms of PPARs. Pharmacol Res 51:85–94
Kovanen PT, Pentikäinen MO (2003) Pharmacological evidence for a role of liver X receptors in atheroprotection. FEBS Lett 536:3–5
Kowala MC, Nunnari JJ, Durham SK, Nicolosi RJ (1991) Doxazin and cholestyramine similarly decrease fatty streak formation in the aortic arch of hyperlipidemic hamsters. Atherosclerosis 91:35–49
Kramer W, Wess G, Enhsen A, Bock K, Falk E, Hoffmann A, Neckermann G, Gantz D, Schulz S, Nickau B, Petzinger E, Turley S, Dietschy JM (1994) Bile acid derived HMG-CoA reductase inhibitors. Biochim Biophys Acta 1227:137–154
Krause BR, Anderson M, Bisgaier CL, Bocan T, Bousley R, DeHart P, Essenburg A, Hamelehle K, Homan R, Kieft K, McNally W, Stanfield R, Newton RS (1993) In vivo evidence that the lipid‐regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J Lipid Res 34:279–294
Krause BR, Black A, Bousley R, Essenburg A, Cornicelli J, Holmes A, Homan R, Kieft K, Sekere C, Shaw-Hes MK, Stanfield R. Trivedi B, Woolf T (1993b) Divergent pharmacological activities of PD 132301–2 and CL 277,082, urea inhibitors of acyl-CoA:cholesterol acyltransferase. J Pharm Exp Ther 267:734–743
Krause BR, Newton SB (1995) Lipid-lowering activity of atorvastatin and lovostatin in rodent species: triglyceride‐lowering in rats correlates with efficacy in LDL animals. Atherosclerosis 117:237–244
Krause BR, Sloop CH, Castle CK, Roheim PS (1981) Mesenteric lymph apolipoproteins in control and ethinyl estradiol‐treated rats: a model for studying apolipoproteins from intestinal origin. J Lipid Res 22:610–619
Krause R, Neubauer H, Leven M, Kesseler K (1990) Inhibition of cholesterol synthesis in target tissues and extrahepatic organs after administration of HMG-CoA reductase inhibitors in normolipidaemic rats: organ selectivity and time course of the inhibition. J Drug Dev 3 (Suppl 1):255–257
Kris-Etheron PM, Dietschy J (1997) Design criteria for studies examining individual fatty acid effects on cardiovascular diseases risk factors: human and animal studies. Am J Clin Nutr 65 Suppl:1590S–1596S
Kritchevsky D (1964) Animal techniques for evaluating hypocholesteremic drugs. In: Nodine JH, Siegler PE (eds) Animal and Clinical Pharmacologic Techniques in Drug Evaluation. Year Book Medical Publishers, Inc., Chicago, pp 193–198
Kritchevsky D (1964) Experimental Atherosclerosis. In: Paoletti R (ed) Lipid Pharmacology. Academic Press, New York, London, Chapter 2, pp 63–130
Kritchevsky D, Tepper SA, Davidson LM, Fisher EA, Klurfeld DM (1989) Experimental atherosclerosis in rabbits fed cholesterol-free diets. 13. Interactions of protein and fat. Atherosclerosis 75:123–127
Kubo M, Strott CA (1987) Differential activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase in zones of the adrenal cortex. Endocrinol 120:214–221
Kumai T, Oonuma S, Matsumoto N, Takeba Y, Taniguchi R, Kamio K, Miyazu O, Koitabashi Y, Sekine S, Tadokoro M, Kobayashi S (2004) Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastin, in a rat model of hypertension and hypercholesterolemia. Life Sci 74:2129–2142
Kushwaha RS, Lewis DS, Dee Carey K, McGill Jr HC (1991) Effects of estrogen and progesterone on plasma lipoproteins and experimental atherosclerosis in the baboon (Papio sp.) Arterioscl Thrombos 11:23–31
Largis EE, Wang CH, DeVries VG, Schaffer SA (1989) CL 277,082: a novel inhibitor of ACAT‐catalyzed cholesterol esterification and cholesterol absorption. J Lipid Res 30:681–690
Laufs U, Gertz K, Dirnagl U, Böhm M, Nickenig G, Endres M (2002) Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942:23–30
Lawrence JW, Kroll DJ, Eacho PI (2000) Ligand‐dependent interaction of hepatic acid-binding protein with the nucleus. J Lipid Res 41:1390–1401
Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, Moller DE, Zhou G (2001) Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator‐activated receptor (PPAR)α. J Biol Chem 276:31521–31527
Lee CH, Evans RM (2002) Peroxisome proliferator‐activated receptor-γ in macrophage lipid homeostasis. Trends Endocr Metab 13:331–335
Lee RG, Kelly KL, Sawyer JK et al (2004) Plasma cholestery ester provided by lecithin: cholesterol acyltransferase and acyl-coenzyme a: cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ Res 95:998–1004
Lee SST, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernadez‐Salguero PM, Westphal H, Gonzalez FJ (1995) Targeted disruption of the α isoform of the peroxisome proliferator‐activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 15:3012–3022
Leo C, Chen JD (2000) The SRC family of nuclear receptor coactivators. Gene 245:1–11
Li AC, Binder CJ, Guttierrez A, Brown KK, Plotkin CR, Pattiso JW, Vallendor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK (2005) Different inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ and γ. J Clin Invest 114:1564–1576
Li AC, Brown KK, Silvestre MJ, Willson TM, Paliski W, Glass CK (2000) Peroxisome proliferator‐activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor‐deficient mice. J Clin Invest 106:523–531
Li AC, Glass CK (2004) PPAR- and LXR‐dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res 45:2161–2173
Lindsey S, Harwood HJ (1995) Inhibition of mammalian squalene synthase activity by zaragozig acid A is a result of competitive inhibition followed by mechanism-based irreversible inactivation. J Biol Chem 270:9083–9096
Linton MF, Farese RV, Chiesa G, Grass DS, Chin P, Hammer RE, Hobbs HH, Young SG (1993) Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and apolipoprotein (a). J Clin Invest 92:3029–3037
Linz W, Schölkens BA (1992) Role of bradykinin in the cardiac effects of angiotensin‐converting enzyme inhibitors. J Cardiovasc Pharmacol 20(Suppl 9):S83–S90
Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA (1994) The contribution of bradykinin to the cardiovascular actions of ACE inhibitors. In Lindpaintner K, Ganten D (eds) The Cardiac Renin Angiotensin System. Futura Publ Co., Inc., Armonk, NY, pp 253–287
Linz W, Wiemer G, Schölkens BA (1993) Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardiovasc Pharmacol 22(Suppl 9):S1–S8
Lopez A, Vial R, Gremillion L, Bell L (1971) Automated simultaneous turbidimetric determination of cholesterol in β- and pre-β-lipoproteins. Clin Chem 17:994–997
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Lund EG, Menke JG, Sparrow CP (2003) Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol 23:1169–1177
Lundholm L (1978) Influence of nicotinic acid, nicitrol and ß-pyridicarbinol on experimental hyperlipidemia and atherosclerosis in mini-pigs. Atherosclerosis 29:217–239
Lustalot P, Schuler W, Albrecht W (1961) Comparison of drug actions in a spectrum of experimental anti‐atherosclerotic test systems. In: Garattini S, Paoletti R (eds) Drugs affecting lipid metabolism. Elsevier Publ Comp, Amsterdam, pp 271–276
Lutton C, Ouguerram K, Sauvage M, Magot T (1990) Turnover of [14C]sucrose HDL and uptake by organs in the normal or genetically hypercholesterolemic (RICO) rat using a constant infusion method. Reprod Nutr Dev 30:97–101
Lyle EM, Fujita T, Conner MW, Connolly TM, Vlasuk GP, Lynch JL (1995) Effect of inhibitors of factor Xa or platelet adhesion, heparin, and aspirin on platelet deposition in an atherosclerotic rabbit model of angioplastic injury. J Pharmacol Toxicol Meth 33:53–61
Makheja AN, Bloom S, Muesing R, Simon T, Bailey JM (1989) Anti‐inflammatory drugs in experimental atherosclerosis. 7. Spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate. Atherosclerosis 76:155–161
Malinow MR, McLaughlin P, Papworth L, Naito HK, Lewis L, McNulty WP (1976) A model for therapeutic intervention on established coronary atherosclerosis in a nonhuman primate. In: Day CE (ed) Atherosclerosis Drug Discovery. Plenum Press, New York and London, pp 3–31
Manderson JA, Cocks TM, Campbell GR (1990) Changes in vascular reactivity following endothelial denudation. In: Lee KT, Onodera K, Tanaka K (eds) Atherosclerosis II: Recent Progress in Atherosclerosis Research. Ann NY Acad Sci 598:564–566
Mansuy D, Sassi A, Dansette PM, Plat M (1986) A new potent inhibitor of lipid peroxidation in vitro and in vivo, the hepatoprotective drug anisyldithiolthione. Biochem Biophys Res Commun 135:1015–1021
Mao SJT, Patton JG, Badimon JJ, Kottke BA, Alley MC, Cardin AD (1983) Monoclonal antibodies to human plasma low-density lipoproteins. I. Enhanced binding of 125I-labeled low-density lipoproteins by combined use of two monoclonal antibodies. Clin Chem 29:1890–1897
Mao SJT, Yates MT, Rechtin AN, Jackson RL, Van Sickle WA (1991) Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. J Med Chem 34:298–302
Mark M, Müller P, Maier R, Eisele B (1996) Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res 37:148–158
Marx N, Duez H, Fruchart JC, Staels B (2004) Peroxisome proliferator‐activated receptors and atherogenesis. Regulators of gene expression in vascular cells. Circ Res 94:1168–1178
Mathur SN, Armstrong ML, Alber CA, Spector AA (1981) Hepatic acyl-CoA:cholesterol acyltransferase activity during diet-induced hypercholesterolemia in cynomolgus monkeys. J Lipid Res 22:659–667
Matsuda K (1994) ACAT inhibitors as antiatherosclerotic agents: Compounds and mechanisms. Med Res Rev 14:271–305
Mauro VF, MacDonald JL (1991) Simvastatin: A review of its pharmacology and clinical use. DICP, Annal Pharmacother 25:257–264
McCarthy PA (1993) New approaches to atherosclerosis: An overview. Med Res Rev 13:139–159
McLean LR, Hagaman KA (1989) Effect of probucol on the physical properties of low-density lipoproteins oxidized by copper. Biochemistry 28:321–327
McTaggart F, Brown GR, Davidson RG, Freeman S, Holdgate GA, Mallion KB, Mirrlees DJ, Smith GJ, Ward WH (1996) Inhibition of squalene synthase of rat liver by novel 3′substituted quinuclidines. Biochem Pharmacol 51:1477–1487
Meier KS, Leitersdorf E (2004) Atherosclerosis in the apolipoprotein E-deficient mouse; a decade of progress. Arterioscler Thromb Vasc Biol 24:1006–1014
Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, Feingold KR (2000) Up‐regulation of peroxisome proliferator‐activated receptors (PPA-α) and PPR-γ messenger ribonucleic acid expression in the liver in murine obesity: triglitazone induces expression of PPAR-γ responsive adipose tissue‐specific genes in the liver of obese mice. Endocrinology 141:4021–4031
Millar JS, Cromley DA, McCoy MG, Rader DJ, Billheimer JT (2005) Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res 46:2032–2028
Miller LR, Pinkerton FT, Schroepfer GJ (1980) 5α-Cholest-8(14)-en-3β-ol-15-one, a potent inhibitor or sterol synthesis, reduces the levels of activity of enzymes involved in the synthesis and reduction of 3-hydroxy-3-methylglutaryl coenzyme A in CHO-K1 cells. Biochem Intern 1:223–228
Ming-Peng S, Ren-Yi X, Bi-Fang R, Zong-Li W (1990) High density lipoproteins and prevention of experimental atherosclerosis with special reference to tree shrews. Ann New Acad Sci 598:339–351
Mitani H, Egashira K, Kimura M (2003b) HMG-Ca reductase inhibitor, fluvastatin, has cholesterol‐lowering independent "direct`` effects on atherosclerotic vessels in high cholesterol diet-fed rabbits. Pharmacol Res 48:417–427
Mitani H, Egashira K, Ohashi N, Yoshikawa M, Niwa S, Nonomura K, Nakashima A, Kimura M (2003a) Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits. Pharmacology 68:121–130
Moore KJ, Rosen RD, Fitzgerald ML, Randow F, Andersson LP, Altshuler D (2001) The role of PPARγ in macrophage differentiation and cholesterol uptake. Nat Med 7:41–47
Moore WR, Schatzman GL, Jarvi ET, Gross RS, McCarthy JR (1992) Terminal difluoro olefin analogues of squalene are time‐dependent inhibitors of squalene epoxidase. J Am Chem Soc 114:360–361
Morand OH, Aebi JD, Dehmlow H, Ji Y-H, Gains N, Lengsfeld H, Himber J (1997) Ro 48–8071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastin. J Lipid Res 38:373–390
Moss JN, Dajani EZ (1971) Antihyperlipidemic agents. In: Turner RA, Hebborn P (eds) Screening Methods in Pharmacology. Vol. II. Academic Press, New York and London, pp 121–143
Murase T, Uchimura H (1980) A selective decline of postheparin plasma hepatic triglyceride lipase in hypothyroid rats. Metabolism 29:797–801
März W, Scharnagel H, Siekmeier R, Träger L, Gross W (1989) Fast lipoprotein chromatography (FPLC) of plasma lipoproteins. J Clin Chem Clin Biochem 27:719
März W, Siekmeier R, Scharnagl H, Seiffert UB, Gross W (1993) Fast lipoprotein chromatography: a new method of analysis for plasma lipoproteins. Clin Chem 39:2276–2281
Müller KR, Li JR, Dinh DM, Subbiah MTR (1979) The characteristics and metabolism of a genetically hypercholesterolemic strain of rats (RICO). Biochim Biophys Acta 574:334–343
Nagata Y, Yonemoto M, Iwasawa Y, Shimuzi‐Nagumo A, Hattori H, Sawazaki Y, Kamei T (1995) N-[2-[N'-Pentyl-(6,6-dimethyl-2,4-heptadinyl)amino]ethyl]-(2-methyl-1-naphthylthio)acetamide (FY-087). A new acyl coenzyme A:cholesterol acyltransferase (ACAT) inhibitor of diet-induced atherosclerosis formation in mice. Biochem Pharmacol 49:643–651
Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R (1994) ApoE‐deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14:133–140
Nervi F, Brinfman M, Allalón W, Depiereux E, Del Pozo R (1984) Regulation of biliary cholesterol secretion in the rat. Role of hepatic esterification. J Clin Invest 74:2226–2237
Ness GC, Zhao Z, Keller RK (1994) Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthesis enzymes, LDL receptor, and cholesterol 7-alpha‐hydroxylase. Arch Biochem Biophys 311:277–285
Nilsson-Ehle P, Schotz MC (1976) A stable, radioactive substrate emulsion for assay of lipoprotein lipase. J Lipid Res 17:536–541
Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H, Sugiyama Y (2003) Lipid-lowering properties of TAK-475, a squalene synthase inhibitor in vivo and in vitro. Br J Pharmacol 139:911–918
Nistor A, Bulla A, Filip DA, Radu A (1987) The hyperlipidemic hamster as a model of experimental atherosclerosis. Atherosclerosis 68:159–173
Nuclear Receptors Nomenclature Committee (1999) A unified nomenclature system for the nuclear receptor superfamily. Cell 97:161–163
O'Brien PM, Sliskovic DR (1992) ACAT inhibitors: A potential new approach to the treatment of hypercholesterolaemia and atherosclerosis. Curr Opin Ther Pat 2:507–526
O'Meara NMG, Devery RAM, Owens D, Collins PB, Johnson AH, Tomkin GH (1991) Serum lipoproteins and cholesterol metabolism in two hypercholesterolaemic rabbit models. Diabetologia 34:139–143
Oehlschlager AC, Singh SM, Sharma S (1991) Squalene synthetase inhibitors: synthesis of sulfonium ion mimics of the carbocationic intermediates. J Org Chem 56:3856–3861
Ogishima T, Okuda K (1986) An improved method for assay of cholesterol 7α-hydroylase activity. Anal Biochem 158:228–232
Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HF, Sternbach DD, Kliewer SA, Hansen BC, Wilson TM (2001) The peroxisome proliferator‐activated receptor δ promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306–5311
Ougueram K, Magot T, Lutton C (1991) Alterations in cholesterol metabolism in the genetically hypercholesterolemic RICO rat: an overview. In: Malmedier CL, Alaupovic P, Brewer Jr HB (eds) Hypercholesterolemia, hypocholesterolemia, hypertriglyceridemia, in vivo kinetics. Adv Exp Med Biol 285:257–274. Plenum Press, New York and London
Ougueram K, Magot T, Lutton C (1992) Metabolism of intestinal triglyceride-rich lipoproteins in the genetically hypercholesterolemic rat (RICO). Atherosclerosis 93:210–208
Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D (1990) Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Atherosclerosis 10:316–323
Paigen B, Morrow A, Brandon C, Mitchell D, Holmes P (1985) Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57:65–73
Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA (1987) Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68:231–240
Parish EJ, Nanduri VBB, Kohl HH, Taylor FR (1986) Oxysterols: Chemical synthesis, biosynthesis and biological activities. Lipids 21:27–30
Parker RA, Clark RW, Sit SY, Lanier TL, Grosso RA, Wright JJ (1990) Selective inhibition of cholesterol synthesis in liver vs. extrahepatic tissues by HMG CoA reductase inhibitors. J Lipid Res 31:1271–1282
Parker RA, Huang Q, Tesfamariam B (2003) Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature. Atherosclerosis 169:19–29
Parthasarathy S, Wieland E, Steinberg D (1989) A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 86:1046–1050
Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D (1986) Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77:641–644
Pearce BC, Parker RA, Deason ME, Qureshi AA, Kim Wright JJ (1992) Hypocholesterolemic activity of synthetic and natural tocotrienols. J Med Chem 35:3595–3606
Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ (1998) Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell 93:693–704
Petty KJ (1995) Tissue- and cell-specific distribution of proteins that interact with the human thyroid receptorβ. Mol Cell Endocrinol 108:131–142
Philipp BW, Shapiro DJ (1979) Improved methods for the assay and activation of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Lipid Res 20:588–593
Picard JA (1993) ACAT inhibitors. Curr Opin Ther Pat 3:151–160
Pineda Torra I, Gervois P, Stels B (1999) Peroxisome proliferator‐activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 10:151–159
Planke MO, Olivier P, Clavey V, Marzin D, Fruchart JC (1988) Aspects of cholesterol metabolism in normal and hypercholesterolemic Syrian hamster. Methods Find Exp Clin Pharmacol 10:575–579
Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL (1992) Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343–353
Princen HMG, Meijer P (1990) Maintenance of bile acid synthesis and cholesterol 7α-hydroxylase activity in cultured rat hepatocytes. Biochem J 272:273–275
Purcell-Huynh DA, Farese RV, Johnson DF, Flynn LM, Pierotti V, Newland DE, Linton MF, Young SG (1995) Transgenic mice expressing high levels of human apoliprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest 95:2246–2257
Raiteri M, Amaboldi L, McGeady P, Gelb MH, Veri D, Tagliabue C, Quarato P, Ferraboschi P, Santaniello E, Paoletti R, Fumagalli R, Corsini A (1997) Pharmacological control of mevalonate pathway: Effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 281:1144–1153
Rankin SM, Parthasarathy S, Steinberg D (1991) Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. J Lipid Res 32:449–456
Reardon CA, Getz GS (2001) Mouse models of atherosclerosis. Curr Opin Lipidol 12:167–173
Reginato MJ, Krakow Sl, Bailley ST, Lazar MA (1998) Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator‐activated receptor γ. J Biol Chem 273:1855–1858
Repa JJ, Buhmann KK, Farese RV Jr et al (2004) ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: impact on hepatic cholesterol homeostasis. Hepatology 40:1088–1097
Richterich R, Lauber K (1962) Bestimmung des Gesamt‐Cholesterins im Serum. VIII. Mitteilung über Ultramikromethoden im klinischen Laboratorium. Klin Wschr 40:1252–1256
Ricote M, Huang JT, Welch JS, Glass CK (1999) The peroxisome proliferator‐activated receptor (PPARγ) as a regulator of monocyte/macrophage function. J Leukoc Biol 66:733–739
Rieusset J, Auwerx J, Vidal H (1999) Regulation of gene expression by activation of the peroxisome proliferator‐activated receptor γ with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265:265–271
Riezebos J, Vleeming W, Beems RB, van Amsterdam JGC, Meijer GW, de Wildt DJ, Porsius AJ, Wemer J (1994) Comparison of Israpidine and Ramipril in cholesterol-fed rabbits: effect on progression of atherosclerosis and endothelial dysfunction. J Cardiovasc Pharmacol 23:415–423
Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, Nishi H, Inoue N, Yokoyama M (2001) Anti‐oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed-rabbits. Atherosclerosis 154:87–96
Riottot M, Olivier Ph, Huet A, Caboche JJ, Parquet M, Khallou J, Lutton C (1993) Hypolipidemic effects of β-cyclodextrin in the hamster and in the genetically hypercholesterolemic RICO rat. Lipids 28:181–188
Roark WH, Roth BC (1994) ACAT inhibitors: preclinical profiles of clinical candidates. Exp Opin Invest Drugs 3:1143–1152
Roberts A, Thompson JS (1976) Inbred mice and their hybrids as an animal model for atherosclerosis research. In: Day CE (ed) Atherosclerosis Drug Discovery. Plenum Press, New York and London, pp 313–327
Rodgers JB (1969) Assay of acyl-CoA:monoglyceride acyltransferase from rat small intestine using continuous recording spectroscopy. J Lipid Res 10:427–432
Rodwell VW, Nordstrom JL, Mitschelen JJ (1976) Regulation of HMG-CoA reductase. In: Paoletti R, Kritchevsky D (eds) Advances in Lipid Research Vol 14:1–74, Academic Press, New York
Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM (2000) Transcriptional regulation of adipogenesis. Genes Dev 14:1293–1307
Rosenberg SH (1998) Squalene synthase inhibitors. Exp Opin Ther Pat 8:521–530
Rosenfeld ME, Tsukada T, Gown AM, Ross R (1987) Fatty streak initiation in Watanabe heritable hyperlipemic and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis 7:9–23
Roth BD, Blankley CJ, Hoefle ML, Holmes A, Roark WH, Trivedi BK, Essenburg AD, Kieft A, Krause BR, Stanfield RL (1992) Inhibitors of acyl CoA:cholesterol acyltransferase. 1. Identification and structure‐activity relationships of a novel series of fatty acid anilide hypocholesterolemic agents. J Med Chem 35:1609–1617
Rothblatt GH, Naftulin M, Arbogast LY (1977) Stimulation of acyl-CoA:cholesterol acyltransferase activity by hyperlipemic serum lipoproteins. Proc Soc Exp Biol Med 155:501–506
Rubanyi GM, Lorenz RR, Vanhoutte PM (1985) Bioassay of endothelium‐derived relaxing factor(s): inactivation by catecholamines. Am J Physiol 249:H95–H110
Rubin EM, Ishida BY, Clift SM, Krauss RM (1991) Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci USA 88:434–438
Rudman D, Brown SJ, Malkin MF (1963) Adipokinetic actions of adrenocorticotropin, thyroid‐stimulating hormone, vasopressin, α- and β-melanocyte‐stimulating hormones, fraction H, epinephrine and norepinephrine in the rabbit, guinea pig, hamster, rat and dog. Endocrinology 72:527–543
Ryder NS (1992) Terbenafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 126: Suppl 39:2–7
Saito Y, Kitahara MKS, Sakashita MSK, Toyoda KSK, Shibazaki TSK (1993) Novel inhibitors of atherosclerotic intimal thickening. Curr Opin Therap Patents 3:1241–1242
Saltykow S (1908) Die experimentell erzeugten Arterienveränderungen in ihrer Beziehung zu Atherosklerose und verwandten Krankheiten des Menschen. Zentralbl Allgem Pathol Pathol Anat 19:321–368
Sasan DA, Newland DE, Tao R, Marcovina S, Wang J, Mooser V, Hammer RE, Hobbs HH (1998) Low density lipoprotein receptor‐negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(s). Proc Natl Acad Sci USA 95:4544–4549
Sata M, Nishimatsu H, Suzuki E, Sugiura S, Yoshizumi M, Ouchi Y, Hirata Y, Ngai R (2001) Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastin to promote collateral growth ion response to ischemia. FASEB J 15:2530–2532
Savkur RS, Bramlett KS, Clawson D, Burris TP (2004) Pharmacology of nuclear receptor‐coregulator recognition. Vitam Horm 68:145–183
Sawada M, Matsuo M, Hagihara H, Tenda N, Nagayoshi A, Okumura H, Washizuka KI, Seki J, Goto T (2001) Effect of FR194738, a potent inhibitor of squalene epoxidase, on cholesterol metabolism in HepG2 cells. Eur J Pharmacol 431:11–16
Sawada M, Washizuka K, Okumura H (2004) Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738. Bioorg Med Chem Lett 14:633–637
Schmitz G, Niemann R, Brennhausen B, Krause R, Assmann G (1985) Regulation of high density lipoprotein receptors in cultured macrophages: role of acyl-CoA:cholesterol acyltransferase. EMBO J 4:2773–2779
Schneider WJ, Brown MS, Goldstein JL (1983) Kinetic defects in the processing of the low density lipoprotein receptor in fibroblasts from WHHL rabbits and a family with familial hypercholesterolemia. Mol Biol Med 1:353–367
Scholz W, Albus U, Hropot M, KLaus E, Linz W, Schölkens BA (1990) Zunahme des Na+/H+-Austausches an Kaninchenerythrozyzen unter atherogener Diät. In: Assmann G, Betz E, Heinle H, Schulte H (eds) Arteriosklerose. Neue Aspekte aus Zellbiologie und Molekulargenetik, Epidemiologie und Klinik. Tagung der Deutschen Gesellschaft für Arteriosklerose‐Forschung. pp 296–302
Schotz MC, Scanu A, Page IH (1957) Effect of Triton on lipoprotein lipase of rat plasma. Am J Physiol 188:399–402
Schurr PE, Schultz JR, Day CE (1976) High volume screening procedures for hypobetalipoproteinemic activity in rats. In: Day CE (ed) Atherosclerosis Drug Discovery. Plenum Press, New York and London, pp 215–229
Schäfer H-L, Linz W, Bube A, Falk E, Hennig A, Hoffmann A, Leineweber M, Matthäi U, Schmalz M, Sendlbeck E, Kramer W, Schölkens BA (1999) The Syrian hamster as animal model for atherosclerosis. Naunyn‐Schmiedeberg's Arch Pharmacol 359S: R111
Scott WA (1990) Hydrophilicity and the differential pharmacology of pravastin. In: Wood C (ed) Lipid management: Pravastin and the differential pharmacology of HMG-CoA reductase inhibitors. Royal Soc Medi Serv, Round Table Series, No 16:17–25
Scott WA (1990) Hydrophilicity and the differential pharmacology of pravastin. In: Wood C (ed) Lipid management: Pravastin and the differential pharmacology of HMG-CoA reductase inhibitors. Royal Society of Medicine Services, London, pp 17–25
Sen SE, Prestwich GD (1989) Squalene analogs containing isopropylidene mimics as potential inhibitors of pig liver squalene epoxidase and oxidosqualene cyclase. J Med Chem 32:2152–2158
Shapiro DJ, Rodwell VW (1969) Diurnal variation and cholesterol regulation of hepatic HMG-CoA reductase activity. Biochem Biophys Res Commun 37:687–872
Shaw MK, Newton RS, Sliskovic DR, Roth BD, Ferguson E, Krause BR (1990) HEP-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase. Biochem Biophys Res Commun 170:726–734
Shefer S, Hauser S, Lapar V, Mosbach EH (1972) Diurnal variation of HMG CoA reductase activity in rat intestine. J Lipid Res 13:571–573
Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN (2003) Direct anti‐inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 108:2113–2120
Shore B, Shore V (1976) Rabbits as a model for the study of hyperlipoproteinemia and atherosclerosis. In: Day CE (ed) Atherosclerosis Drug Discovery. Plenum Press, New York and London, pp 123–141
Siedel J, Hägele EO, Ziegenhorn J, Wahlefeld AW (1983) Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 29:1075–1080
Simpson CF, Harms RH (1969) Aortic atherosclerosis of turkeys induced by feeding of cholesterol. J Atheroscler Res 10:63–75
Sirtori CR (1990) Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Pharmacol Res 22:555–563
Slayback JRB, Cheung LWY, Geyer RP (1977) Quantitative extraction of microgram amounts of lipid from cultured human cells. Anal Biochem 83:372–384
Sliskovic DR, Picard JA (1997) Squalene synthase inhibitors. Emerg Drugs 2:93–107
Sliskovic DR, White AD (1991) Therapeutic potential of ACAT inhibitors as lipid lowering and anti‐atherosclerotic agents. Trends Pharmacol Sci 12:194–199
Soma MR, Corsini A, Paoletti R (1992) Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett 64/65:1–15
Soma MR, Donetti E, Paroline C, Mazzini G, Ferrari C, Fumagalli R, Paoletti R (1993) HMG-CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thrombos 13:571–578
Soret MG, Blanks MC, Gerritsen GC, Day CE, Block EM (1976) Diet-induced hypercholesterinemia in the diabetic and non-diabetic Chinese hamster. In: Day CE (ed) Atherosclerosis Drug Discovery. Plenum Press, New York and London, pp 329–343
Sparrow CP, Baffic J, Lam MH, Lund EG, Adams AD, Fu X, Hayes N, Jones AB, Macnaul KL, Ondeyka J, Singh S, Wang J, Zhou G, Moller DE, Wright SD, Menke JG (2002) A potent synthetic LXR agonist is more effective than cholesterol loading and inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem 277:10021–10027
Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski‐Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD (2001) Simvastin has anti‐inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21:115–121
Spencer TA, Li D, Russel JS, Collins JL, Bledsoe RK, Consler TG, Moore LB, Galardi CM, McKee DD, Moore JT, Watson MA, Parks DJ, Lambert MH, Willson TM (2001) Pharmacophore analysis of the nuclear oxysterol receptor LXRα . J Med Chem 44:886–897
Sperry WM (1956) Lipid analysis. In: Glick D (ed) Methods in biochemical analysis, Vol. II, pp 83–111
Sprague EA, Kothapalli R, Kerbacher JJ, Edwards EH, Schwartz CJ, Elbein AD (1993) Inhibition of scavenger receptor‐mediated modified low-density lipoprotein endocytosis in cultured bovine aortic endothelial cells by the glycoprotein processing inhibitor castanospermine. Biochemistry 32:8888–8895
Staels B (2001) Regulation of lipid and lipoprotein metabolism by retinoids. J Am Acad Dermatol 45:S158–S167
Steinberg D (1990) Arterial metabolism of lipoproteins in relation to atherogenesis. In: Lee KT, Onodera K, Tanaka K (eds) Atherosclerosis II: Recent Progress in Atherosclerosis Research. Ann NY Acad Sci 598:188–193
Steinberg D, Parthasaraty S, Carew TE (1988) In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am J Cardiol 62:6B–12B
Steinbrecher UP (1987) Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 262:3603–3608
Steinbrecher UP (1990) Oxidatively modified lipoproteins. Curr Opin Lipidol 1:411–415
Steinbrecher UP, Witztum JL, Parthasarathy S, Steinberg D (1987) Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Arteriosclerosis 7:135–143
Steinbrecher UP, Zhang H, Lougheed M (1990) Role of oxidatively modified LDL in atherosclerosis. Free Rad Biol Med 9:155–158
Stoltzfus L, Rubin EM (1993) Atherogenesis. Insights from the study of transgenic and gene-targeted mice. Trends Cardiovasc Med 3:130–134
Suckling KE, Benson GM, Bond B, Gee A, Glen A, Haynes C, Jackson B (1991) Cholesterol lowering and bile acid excretion in the hamster with cholestyramine treatment. Atherosclerosis 89:183–190
Suckling KE, Boyd GS, Smellie CG (1982) Properties of a solubilised and reconstituted preparation of acyl-CoA:cholesterol acyltransferase from rat liver. Biochem Biophys Acta 710:154
Sugiyama Y, Ishikawa E, Odaka H, Miki N, Tawada H, Ikeda H (1995) TMP-153, a novel ACAT inhibitor, inhibits cholesterol absorption and lowers cholesterol in rats and hamsters. Atherosclerosis 113:71–78
Sullivan PM, Mazdour H, Quarfordt SH, Maeda N (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse ApoE with human ApoE*2. J Clin Invest 102:130–135
Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, Matsui H, Iguchi A (2001) A HMG-CoA reductase inhibitor possesses a potent anti‐atherosclerotic effect other than lipid lowering effects – the relevance of endothelial nitric oxide reductase and superoxide anion scavenging action. Atherosclerosis 155:347–357
Tagawa H, Tomoike H, Nakamura M (1991) Putative mechanisms of the impairment of endothelium‐dependent relaxation of the aorta with atheromatous plaque in heritable hyperlipidemic rabbits. Circ Res 68:330–337
Tai HH, Bloch K (1972) Squalene epoxidase of rat liver. J Biol Chem 247:3767–3773
Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fiévet C (2003) Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipemia and atherosclerosis. Trend Pharmacol Sci 24:530–534
Takano T, Mowri HO (1990) Peroxidized lipoproteins recognized by a new monoclonal antibody (DLR1a/104G) in atherosclerotic lesions. In: Lee KT, Onodera K, Tanaka K (eds) Atherosclerosis II: Recent Progress in Atherosclerosis Research. Ann NY Acad Sci 598:136–142
Tamasi G, Borsy J, Patthy A (1968) Comparison of the anti-lipemic effect of nicotinic acid (NA) and 4-methylpyrazole-5-carboxylic acid (MPC) in rats. Biochem Pharmacol 17:1789–1794
Tanaka H, Kimura T (1994) ACAT inhibitors in development. Exp Opin Invest Drugs 3:427–436
Tanaka H, Ohtsuka I, Kogushi M, Kimura T, Fujimori T, Saeki T, Hayashi K, Kobayashi H, Yamada T, Hiyoshi H, Saito I (1994) Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis 107:187–210
Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Mgoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yagishawa M, Kodama T, Sakai J (2003) Activation of peroxisome proliferator‐activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100:15924–15929
Tangirala RK, Bishoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL, Thomas DA, Heyman RA, Mangelsdorf DJ, Wang X, Lusis AJ, Tontonoz P, Scholman IG (2002) Identification of liver XC receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 99:11896–11901
Tao L, Liu HR, Gao E, Teng ZP, Lopez BL, Christopher TA, Ma XL, Batinic‐Haberle I, Willette RN, Ohlstein EH, Yue TL (2003) Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator‐activated receptor-γ agonist in hypercholesterolemia. Circulation 108:2805–2811
Telford DE, Edwards JY, Lipson SM, Hugh P, Barrett HP, Burnett JR, Krul ES, Keller BT, Huff MW (2003) Inhibition of both the apical sodium‐dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB. J Lipid Res 44:943–952
Tennent DM, Siegel H, Zanetti ME, Kuron GW, Ott WH, Wolf FJ (1960) Plasma cholesterol lowering action of bile acid binding polymers in experimental animals. J Lipid Res 1:469–473
Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T (2003) T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor‐deficient mice. FEBS Lett 536:6–11
Toda H, Kihara K, Hashimoto M, Mizogami S (1988) Bile acid binding and hypocholesterolemic activity of a new anion exchange resin from 2-methylimidazol and epichlorhydrin. J Pharm Sci 77:531–533
Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM (1988) PPARγ promotes monocytes/macrophages differentiation and uptake of oxidized LDL. Cell 93:241–252
Tordjman K, Bernal‐Mizrachi C, Zermany L, Weng S, Feng C, Zhang F, Leone TC, Coleman T, Kelly DP, Semenkovich CF (2001) PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J Clin Invest 107:1025–1034
Trzaskos JM, Magolda RL, Favata MF, Fischer RT, Johnson PR, Chen HW, Ko SS, Leonard DA, Gaylor JL (1993) Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase by 15α-fluorolanost-7-en-3β-ol. A mechanism-based inhibitor of cholesterol biosynthesis. J Biol Chem 268:22591–22599
Tso P, Morshed KM, Nutting DF (1991) Importance of acyl CoA:cholesterol acyltransferase (ACAT) on the esterification of cholesterol by enterocytes. FASEB J 5:A709
Tsujita Y (1990) A potent HMG-CoA reductase inhibitor, pravastatin sodium. Tissue selective inhibition of cholesterogenesis and preventive effect on atherosclerosis in WHHL rabbits. J Drug Dev 3 (Suppl 1):155–159
Tsujita Y (1990b) HMG-CoA reductase inhibitors. J Jpn Atheroscler Soc 18:165–171
Tsujita Y, Kuroda M, Shimada Y, Tanzawa K, Arai M, Kaneko I, Tanaka M, Masuda H, Tarumi Ch, Watanabe Y, Fujii S (1986) CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue‐selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. Biochim Biophys Acta 877:50–60
Tsusumi K, Inoue Y, Shima A, Iwasaki K, Kawamura M, Murase T (1993) The novel compound NO-1886 increases lipoprotein lipase activity with resulting elevation of high density lipoprotein cholesterol, and long term administration inhibits atherogenesis in the coronary arteries of rats with experimental atherosclerosis. J Clin Invest 92:411–417
Tubbs PK, Garland PB (1969) Assay of coenzyme A and some acyl derivatives. Meth Enzymol 13:535–551
Ugawa T, Kakuta H, Inagaki O (2002) Effect of YM-53691, a novel squalene synthase inhibitor, on the clearance rate ofplasma LDL and VLDL in hamsters. Br J Pharmacol 137:561–569
Ugawa T, Kakuta H, Moritani H, Inagaki O, Shikama H (2003) YM-53601. a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. Br J Pharmacol 139:140–146
Ugawa T, Kakuta H, Moritani H, Matsuda K, Ishihara T, Yamaguchi M, Naganuma S, Iizumi Y, Shikama H (2000) YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 131:63–70
Ugawa T, Kakuta H, Moritani H, Shikama H (2002) Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. Br J Pharmacol 135:1572–1578
Vaidya S, Bostedor R, Kurtz MM, Bergstrom JD, Bansal VS (1998) Massive production of farnesol‐derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. Arch Biochem Biophys 355:84–92
Van Heek M, Compton DS, Davis HR (2001) The cholesterol adsorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 415:79–84
Van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, Davis HR (2000) Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH5835, and its glucuronide, SCH60663. Br J Pharmacol 129:1748–1754
Van Heek M, Farley C, Copton DS, Hoos LM, Smith-Torhan A, Davois HR (2003) Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol 138:1459–1464
Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz CD, Edwards PA, Tontonoz P (2000) Control of cellular efflux by the nuclear oxysterol receptor LXRα. Proc Natl Acad Sci USA 97:12097–12102
Venkateswaran A, Repa JJ, Lobacarro JM, Bronson A, Mangelsdorf DJ, Edwards PA (2000) Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem 275:14700–14707
Verbeuren TJ, Jordaens FH, Van Hove CE, Van Hoydonk AE, Herman AG (1990) Release and vascular activity of endothelium‐derived relaxing factor in atherosclerotic rabbit aorta. Eur J Pharmacol 191:173–184
Verbeuren TJ, Jordaens FH, Zonnekeyn LL, Van Hove CE, Coene MC, Herman AG (1986) Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothelium‐dependent and endothelium‐independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res 58:552–564
Vosper H, Khoudoli GA, Graham TL, Palmer CAN (2002) Peroxisome proliferator‐activated receptor agonists, hyperlipidemia and atherosclerosis. Pharmacol Ther 95:47–62
Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH, Pinto I, Smith SA, Suckling KE, Wolf CR, Palmer CAN (2001) The peroxisome proliferator‐activated receptor δ promotes lipid accumulation in human macrophages. J Biol Chem 276:44258–44265
Vu-Dac N, Schoonjans K, Kosykh, Dallongeville J, Fruchart JC, Staels B, Auwerx J (1995) Fibrates increase human apolipoprotein A-II through activation of the peroxisome proliferators‐activated receptor. J Clin Invest 96:741–750
Wahlefeld AW (1974) Triglyceride. Bestimmung nach enzymatischer Verseifung. In: Bergmeier HU (ed) Methoden der enzymatischen Analyse, 3. Auflage, Band II, Verlag Chemie, pp 1878–1882
Walsh A, Ito Y, Breslow JL (1989) High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J Biol Chem 264:6488–6494
Wang M, Tafuri S (2003) Modulation of PPARγ activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem 89:38–47
Wang YX (2005) Cardiovascular functional phenotypes and pharmacological responses in apolipoprotein E deficient mice. Neurobiol Aging 26:309–316
Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga‐Ocampo CR, Ham J, Kang H, Evans RM (2004) Regulation of muscle fibre type and running endurance by PPARδ. PloS Biol 2:1532–1539
Wassmann S, Nickenig G (2003) Interrelationship of free oxygen radicals and endothelial dysfunction – modulation by statins. Endothelium 10:23–33
Watanabe Y (1980) Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL)-rabbit). Incidence and development of atherosclerosis and xanthoma. Atherosclerosis 36:261–268
Watanabe Y, Ito T, Kondo T (1977) Breeding of a rabbit strain of hyperlipidemia and characteristic of these strain. Exp Anim 26:35–42
Watanabe Y, Ito T, Shiomi M (1985) The effect of selective breeding on the development of coronary atherosclerosis in WHHL rabbits. An animal model for familial hypercholesterolemia. Atherosclerosis 56:71–79
Watanabe Y, Ito T, Shiomi M, Tsujita Y, Kuroda M, Arai M, Fukami M, Tamura A (1988) Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits. Biochim Biophys Acta 960:294–302
Waterham HR, Wanders RJA (2000) Biochemical and genetic aspects of 7-dehydrocholesterol reductase and Smith-Lemli-Opitz syndrome. Biochem Biophys Acta 1529:340–356
Weingand KW, Daggy BP (1990) Quantification of high-density‐lipoprotein cholesterol in plasma from hamsters by differential precipitation. Clin Chem 36:575–576
Weingand KW, Daggy BP (1991) Effects of dietary cholesterol and fasting on hamster lipoprotein lipids. Eur J Clin Chem Clin Biochem 29:425–428
Wess G, Kramer W, Han XB, Bock K, Enhsen A, Glombik H, Baringhaus KH, Böger G, Urmann M, Hoffmann A, Falk E (1994) Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of the 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system. J Med Chem 37:3240–3246
Williams S, Bledsoe RK, Collins JL, Boggs R, Lambert MH, Miller AB, Moore J, McKee DD, Moore L, Nichols J, Parks D, Watson M, Wisely B, Willson TM (2003) X-ray crystal structure of the liver X receptor β ligand binding domain. Regulation by a histidine‐tryptophan twitch. J Biol Chem 278:27138–27143
Willson TM, Brown PJ, Sternbach DD, Henke BR (2000) The PPARs: From orphan receptors to drug discovery. J Med Chem 43:527–550
Willy JP, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ (1995) LXR, a nuclear receptor that defined a distinct retinoid response pathway. Genes Dev 9:1022–1045
Windler E, Rücker W, Greeve J, Reimitz H, Greten H (1990) Influence of the acyl-coenzyme A:cholesterol‐acyltransferase inhibitor octimibate on cholesterol transport in rat mesenteric lymph. Arzneim Forsch/Drug Res 40:1108–1111
Witztum JL, Steinberg D (1991) Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785–1792
Wright SD, Silverstein SC (1982) Tumor promoting phorbol esters stimulate C3b and C3b' receptor‐mediated phagocytosis in cultured human monocytes. J Exp Med 156:1149–1164
Yamaguchi Y, Kitagawa S, Imaizumi N, Kunitomo M, Fujiwara M (1993) Enhancement of cholesterol deposition by dietary linoleic acid in cholesterol-fed mice: an animal model for primary screening of antiatherosclerotic agents. J Pharm Toxicol Meth 30:169–175
Yamamoto A, Takaishi S, Hara H, Nishikawa O, Yokoyama S, Yamamura T, Yamaguchi T (1986) Probucol prevents lipid storage in macrophages. Atherosclerosis 62:209–217
Yamamoto T, Takeda K, Harada S, Nakata T, Azuma A, Sasaki S, Nakagawa M (2003) HMG-CoA reductase inhibitor enhances inducible nitric oxide synthase expression in rat vascular smooth muscle cell; involvement of the Rho/Rho kinase pathway. Atherosclerosis 166:213–222
Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H (2003) Protective effect of HMG CoA reductase inhibitor on experimental renal ischemia‐reperfusion injury. Am J Nephrol 23:13–17
Yoshikawa T, Shimano H, Yahagi N, Ide T, Amemiya-Kudo M, Matsuzaka Z, Nakakuki M, Tomita S, Okazaki H, Tamura Y, Izuka Y, Ohashi K, Takahashi A, Sone H, Osuka JL, Gotoda T, Ishibashi S, Yamada N (2002) Polyunsaturated fatty acids suppress sterol regulatory element‐binding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR responsive elements. J Biol Chem 277:1705–1711
Yoshioka T, Fujita T, Kanai T, Aizawa Y, Kurumada T, Hasegawa K, Horikoshi H (1989) Studies with hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J Med Chem 32:421–428
Yu L, York J, von Bergmann K, Cohen JC, Hobbs HH (2003) Stimulation of cholesterol excretion by liver X receptor agonist requires ATP-binding cassette transporter G5 and G8. J Biol Chem 15565–15570
Zhang H, Basra HJK, Steinbrecher UP (1990) Effects of oxidatively modified LDL on cholesterol esterification in cultured macrophages. J Lipid Res 31:1361–1369
Zhang SH, Reddick RL, Piedrahita JA, Maeda N (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468–471
Zilversmit DB (1972) A single blood sample dual isotope method for the measurement of cholesterol absorption in rats. Proc Soc Exp Biol Med 140:862–865
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag
About this entry
Cite this entry
Vogel, H. (2007). Anti-Atherosclerotic Activity. In: Vogel, H.G. (eds) Drug Discovery and Evaluation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-70995-4_14
Download citation
DOI: https://doi.org/10.1007/978-3-540-70995-4_14
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-71420-0
Online ISBN: 978-3-540-70995-4
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences